Fundraising FoxAbingworth — 2026 Investments
4 investments dated 2026 · listed companies and verified rows first · show all
Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases.
BiotechHealthtechRedwood City, US
Judith Shizuru(Director)Herb Cross(Executive Officer)inJeet Mahal(Executive Officer, Director)inPatrick Crutcher(Director)Svetlana Lucas(Director)Wenru Song(Executive Officer)
Board seatKurt von Emster· per SEC Form D · $132M raise · filed Aug 2026
Co-investorsAvego BioScience CapitalQiming Venture Partners USARoche Venture FundTSVCIkarian Capital
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.
BiotechHealthtechMedical DevicesCambridge, US
Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)inAaron Pickett(Executive Officer)in
BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)
Board seatBali Muralidhar· per SEC Form D
Co-investorsBain Capital Life SciencesCatalio Capital Management, LPProto AxiomSanofi VenturesSV Health InvestorsTenmile+2 more
Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.
BiotechHealthtech
Co-investorsCriteria Bio VenturesLifeArc VenturesMedical Incubator Japan K.K.Modi VenturesPathway BioventuresSound Bioventures+1 more
Co-investorsF-Prime CapitalCurie.Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.